CAS Number10402-53-6
Synonyms3-[4-(2-Ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-1-propanone, dihydrochloride; 3-[4-(2-Ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-1-propanone dihydrochloride; 3-[4-(2-ethoxy-2-phenylethyl)piperazin-1-yl]-2-methyl-1-phenylpropan-1-one dihydrochloride; 3-[4-(2-ethoxy-2-phenylethyl)piperazin-1-yl]-2-methyl-1-phenylpropan-1-one,dihydrochloride; 3-(4-(2-Ethoxy-2-phenylethyl)piperazin-1-yl)-2-methyl-1-phenylpropan-1-one dihydrochloride; Eprazinone dihydrochloride; 1-Propanone, 3-[4-(2-ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-, hydrochloride (1:2); eprazinone di-hcl
Molecular FormulaC24H34Cl2N2O2
Molecular Weight453.45
Purity98.00%
Density1.064 g/cm3
Boiling Point503.9ºC at 760 mmHg
AppearanceA white or nearly white crystal
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 10402-53-6 |
| Catalog No. | 2A-9034855 |
| Chinese Name | 盐酸依普拉酮 |
| Synonyms | 3-[4-(2-Ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-1-propanone, dihydrochloride; 3-[4-(2-Ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-1-propanone dihydrochloride; 3-[4-(2-ethoxy-2-phenylethyl)piperazin-1-yl]-2-methyl-1-phenylpropan-1-one dihydrochloride; 3-[4-(2-ethoxy-2-phenylethyl)piperazin-1-yl]-2-methyl-1-phenylpropan-1-one,dihydrochloride; 3-(4-(2-Ethoxy-2-phenylethyl)piperazin-1-yl)-2-methyl-1-phenylpropan-1-one dihydrochloride; Eprazinone dihydrochloride; 1-Propanone, 3-[4-(2-ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-, hydrochloride (1:2); eprazinone di-hcl |
| Molecular Formula | C24H34Cl2N2O2 |
| Molecular Weight | 453.45 |
| Purity | 98.00 |
| Density | 1.064 g/cm3 |
| Boiling Point | 503.9ºC at 760 mmHg |
| Appearance | A white or nearly white crystal |
| Storage Condition | 2~8℃ |
| Application | Eprazinone dihydrochloride is a drug with mucolytic, secretolytic, antitussive and bronchial antispasmodic properties. Eprazinone dihydrochloride is a ligand for the neurokinin 1 receptor (NK1R). Epra |
| HTC | 2933990090 |
| PubChem ID | 7848169 |
| MDL Number | C24H32N2O2·2HCl |
| SMILES | CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1.Cl.Cl |
| InChI | InChI=1S/C24H32N2O2.2ClH/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22;;/h4-13,20,23H,3,14-19H2,1-2H3;2*1H |
| InChI Key | BPMQVOKMMQFZGV-UHFFFAOYSA-N |
| MSDS | msds/34855_1_10402_53_6.pdf |
| Bioactivity | Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen[1][2]. Related Catalog Research Areas >> Inflammation/Immunology Signaling Pathways >> Neuronal Signaling >> Neurokinin Receptor Signaling Pathways >> GPCR/G Protein >> Neurokinin Receptor Target Neurokinin 1 receptor[1] In Vitro Eprazinone specifically displaces binding to the NK1R. Although Eprazinone displays a rather weak inhibition of [125I]BH-SP binding to NK1R, at a concentration of 25 μM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity[2]. In Vivo Eprazinone (50-200 mg/kg; oral gavage; daily; for 4 days; adult male rats) at a dose of 200 mg/kg significantly increases total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreases total neutral lipids. Lower doses of Eprazinone significantly decrease neutral lipid levels without affecting the phospholipids[1]. In airway epithelial studies, mucosal addition of Eprazinone produces a dose-dependent partially reversible decrease in short-circuit current (Isc). The decrease in Isc at lower Eprazinone concentrations is accounted for entirely by a decrease in net chloride secretion while at higher concentrations both sodium and chloride transport are affected[1]. Animal Model: Adult male pathogen free Fischer 344 inbred rats (200-250 g)[1] Dosage: 50 mg/kg, 100 mg/kg, and 200 mg/kg Administration: Oral gavage; daily; for 4 days Result: At a dose of 200 mg/kg significantly increased total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreased total neutral lipids. References [1]. R S Thrall, et al. Eprazinone Alters Lung Lavage Lipid Levels and Transtracheal Ion Transport. Exp Lung Res. May-Jun 1992;18(3):409-20. [2]. Yvonne Krautscheid, et al. Pharmacophore Modeling, Virtual Screening, and in Vitro Testing Reveal Haloperidol, Eprazinone, and Fenbutrazate as Neurokinin Receptors Ligands. J Chem Inf Model. 2014 Jun 23;54(6):1747-57. Chemical & Physical Properties Density 1.064 g/cm3 Boiling Point 503.9ºC at 760 mmHg Molecular Formula C24H34Cl2N2O2 Molecular Weight 453.445 Flash Point 258.5ºC Exact Mass 452.199738 PSA 32.78000 LogP 5.38060 Vapour Pressure 2.8E-10mmHg at 25°C InChIKey BPMQVOKMMQFZGV-UHFFFAOYSA-N SMILES CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1.Cl.Cl Storage condition 2~8℃ |
| Use of | Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen[1][2]. Properties Name eprazinone hydrochloride Synonym More Synonyms Eprazinone 2HCl Biological Activity Description Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen[1][2]. Related Catalog Research Areas >> Inflammation/Immunology Signaling Pathways >> Neuronal Signaling >> Neurokinin Receptor Signaling Pathways >> GPCR/G Protein >> Neurokinin Receptor Neurokinin 1 receptor[1] In Vitro Eprazinone specifically displaces binding to the NK1R. Although Eprazinone displays a rather weak inhibition of [125I]BH-SP binding to NK1R, at a concentration of 25 μM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity[2]. References [1]. R S Thrall, et al. Eprazinone Alters Lung Lavage Lipid Levels and Transtracheal Ion Transport. Exp Lung Res. May-Jun 1992;18(3):409-20. [2]. Yvonne Krautscheid, et al. Pharmacophore Modeling, Virtual Screening, and in Vitro Testing Reveal Haloperidol, Eprazinone, and Fenbutrazate as Neurokinin Receptors Ligands. J Chem Inf Model. 2014 Jun 23;54(6):1747-57. Chemical & Physical Properties Exact Mass 452.199738 PSA 32.78000 LogP 5.38060 InChIKey BPMQVOKMMQFZGV-UHFFFAOYSA-N Storage condition 2~8℃ |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Calcium aspartate | 10389-09-0 | 2A-9034843 |
| 3-Ethynylphenol | 10401-11-3 | 2A-9034851 |
| Cupric citrate | 10402-15-0 | 2A-9034852 |
| Cupric nitrate | 10402-29-6 | 2A-9034853 |
| 2-Phenylpropyl acetate | 10402-52-5 | 2A-9034854 |
| 2-Bromo-5-nitroaniline | 10403-47-1 | 2A-9034857 |
| 1,2-Di(phenoxymethyl)benzene | 10403-74-4 | 2A-9034858 |
| Trospium chloride | 10405-02-4 | 2A-9034859 |
| 3-Cyanobenzylamine | 10406-24-3 | 2A-9034862 |
| 4-Cyanobenzylamine | 10406-25-4 | 2A-9034863 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS